|
|
|
|
Tizanidine produced a significantly greater reduction than placebo in spasms and clonus(patient diaries)but no significant differences in Ashworth scores.Patients and physician/prescribers,but not physician/ assessors,gave significantly better scores in the overall assessment of efficacy and tolerability.No significant differences in other secondary efficacy parameters were noted.Adverse events were reported for 66(61%)of the 109 placebo-treated patients and 101(91%)of the 111 tizanidine-treated patients;6(6%)and 14(13%)discontinued treatment,respectively.Patient and physician perception of improvement demonstrated more consistent differences between groups than did the Ashworth Scale,perhaps because of inexperience with this measure or failure to consider time between drug administration and assessment. |
|